Shares of US protein-based vaccine maker Novavax closed down 19.4% at $10.15 yesterday having dropped as much as 24%, on the ...

In the latest market close, Novavax (NVAX) reached $10.35, with a +1.97% movement compared to the previous day. The stock ...

A report of a case of motor neuropathy in a patient who received the vaccine last year has led the FDA to halt its ...

After a lengthy COVID-19 surge this summer, the Bay Area is about to enter the winter respiratory virus season. Explore our ...

Novavax announced Wednesday that the Food and Drug Administration (FDA) has placed a clinical hold on its application for a ...

Factors associated with increased flare rates post-vaccination included active disease at the time, female sex, and -- most ...

Nigeria took a significant step in its fight against malaria by launching the R21 malaria vaccine on Thursday, which will be ...

It will become one of the first countries to roll out the new malaria vaccine, R21, after receiving a first batch of 846,200 ...

The report involved motor neuropathy in a participant of the phase 2 trial conducted outside the U.S., according to an Oct. 16 news release from the company. The participant received the vaccine in ...

Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.

Standing desks may increase the risk of swollen veins and blood clots, a study in the International Journal of Epidemiology ...

CIDRAP reports that federal health officials know of 90 cases of Oropouche virus from five states, mostly from Florida, although none of the cases is known to have been sexually transmitted. Plus: ...